Vera Therapeutics (VERA) Net Cash Flow (2020 - 2026)

Vera Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$240.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 540.04% year-over-year to -$240.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.3 million (up 522.84% YoY), and the FY2025 full-year result was $262.1 million, up 458.03% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$240.4 million, down from $297.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $297.0 million in Q4 2025, with the low at -$240.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged $2.0 million across 5 years, with a median of $2.2 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 867.22% — and 2026, when it sank 540.04%.
• Vera Therapeutics' Net Cash Flow stood at $13.0 million in 2022, then soared by 40.48% to $18.2 million in 2023, then surged by 258.5% to $65.4 million in 2024, then surged by 354.12% to $297.0 million in 2025, then plunged by 180.95% to -$240.4 million in 2026.
• The last three Net Cash Flow figures came in at -$240.4 million (Q1 2026), $297.0 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.